TMC207 is a first-in-class anti-TB diarylquinoline (also named R207910 or the 'J' compound) with activity against drug-sensitive and drug-resistant TB. TMC207 inhibits the proton pump of mycobacterial ...

Researchers have found that approved drugs that were originally shown to normalize blood vessels surrounding tumors (to improve drug delivery to cancer cells) can enhance the delivery of ...

Researchers from the University of Sydney and the Centenary Institute have discovered how a promising class of experimental ...

Despite newer TB drugs, delayed diagnosis, atypical symptoms and drug resistance continue to complicate treatment ...

A new study published in the American Society for Microbiology journal Microbiology Spectrum demonstrates that a novel semi-synthetic compound can be derived from natural compounds to produce potent ...

Researchers from the University of Sydney and the Centenary Institute have discovered how a promising class of experimental antibiotics disrupts the bacterium that causes tuberculosis (TB), paving the ...

Researchers used data from large studies that contained laboratory measurements of two-drug combinations of 12 anti-tuberculosis drugs. Using mathematical models, the team discovered a set of rules ...

An international research team headed by scientists at the University of British Columbia has demonstrated how a novel semi-synthetic compound derived from sanguinarine (SG), an alkaloid extracted ...

BOSTON – Tuberculosis (TB) is often overlooked in developed countries such as the United States, but this bacterial infection remains one of the deadliest diseases globally and results in millions of ...